Biote announcesTerry Weber retires Bret Christensen named CEO

biote (BTMD) announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company’s Board of Directors, effective as of February 1. She will be transitioning to Strategic Advisor to the Company’s Board of Directors. Concurrently, Bret Christensen has been named Chief Executive Officer and Director, effective February 1 . “On behalf of the Board, I want to thank Terry for her many contributions to Biote’s success over the past six years. Under Terry’s leadership, Biote has grown to become one of the nation’s leading educators in hormone optimization, with over 7,000 Biote-certified practitioners advancing patient health and well-being throughout the country,” said Marc Beer, Executive Chairman of the Board of Directors. Mr. Christensen is a distinguished executive with over two decades of leadership experience in women’s health and the broader health care sector. Throughout his career, Mr. Christensen has consistently worked to advance health care offerings into industry standards, demonstrating an outstanding ability to launch innovative solutions, penetrate markets and effectively scale businesses. “On behalf of the Board of Directors, I am delighted to welcome Bret to Biote,” Mr. Beer said. “In his prior commercial and general management leadership roles at Hologic (HOLX), Myriad Genetics (MYGN) and Insulet (PODD), Bret helped revolutionize treatments in women’s health care, oncology and diabetes, generating profitable growth and achieving significant commercial success of numerous products. With his deep expertise spanning the diagnostic, therapeutic and medical device health care sectors, we believe Bret is exceptionally qualified to lead Biote’s next level of growth and help drive value creation for Biote stakeholders.”